Porter DL - Search Results

1

Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas.

Shah NN, Nagle SJ, Torigian DA, Farwell MD, Hwang WT, Frey N, Nasta SD, Landsburg D, Mato A, June CH, Schuster SJ, Porter DL, Svoboda J. Shah NN, et al. Among authors: porter dl. Cytotherapy. 2018 Dec;20(12):1415-1418. doi: 10.1016/j.jcyt.2018.10.003. Epub 2018 Oct 29. Cytotherapy. 2018. PMID: 30385043

2

Use of EBV PCR for the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patients.

Tsai DE, Nearey M, Hardy CL, Tomaszewski JE, Kotloff RM, Grossman RA, Olthoff KM, Stadtmauer EA, Porter DL, Schuster SJ, Luger SM, Hodinka RL. Tsai DE, et al. Among authors: porter dl. Am J Transplant. 2002 Nov;2(10):946-54. doi: 10.1034/j.1600-6143.2002.21011.x. Am J Transplant. 2002. PMID: 12482147 Free article.

3

Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation.

Laport GG, Levine BL, Stadtmauer EA, Schuster SJ, Luger SM, Grupp S, Bunin N, Strobl FJ, Cotte J, Zheng Z, Gregson B, Rivers P, Vonderheide RH, Liebowitz DN, Porter DL, June CH. Laport GG, et al. Among authors: porter dl. Blood. 2003 Sep 15;102(6):2004-13. doi: 10.1182/blood-2003-01-0095. Epub 2003 May 22. Blood. 2003. PMID: 12763934 Free article. Clinical Trial.

4

Homocysteine and prothrombin fragment 1+2 levels in patients with veno-occlusive disease after stem cell transplantation.

Gerecitano J, Mathias C, Mick R, Duffy KM, Luger S, Stadtmauer EA, Schuster SJ, Tsai D, Nasta S, Berlin J, Phillips DK, High KA, Porter DL. Gerecitano J, et al. Among authors: porter dl. J Hematother Stem Cell Res. 2003 Apr;12(2):215-23. doi: 10.1089/152581603321628359. J Hematother Stem Cell Res. 2003. PMID: 12804180

5

Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody.

Tsai DE, Maillard I, Schuster SJ, Nasta SD, Porter DL, Klumpp TR, Goldenberg DM, Luger SM, Alavi A, Sharkey RM, Hartzell KB, Stadtmauer EA. Tsai DE, et al. Among authors: porter dl. Clin Lymphoma. 2003 Jun;4(1):56-9. doi: 10.3816/clm.2003.n.015. Clin Lymphoma. 2003. PMID: 12837157

6

Leukemic gingival infiltrate as an indicator of chemotherapeutic failure following monoclonal antibody therapy: a case report.

Sollecito TP, Draznin J, Parisi E, Duffy K, Stadtmauer EA, Luger SM, Schuster SJ, Tsai D, Porter DL. Sollecito TP, et al. Among authors: porter dl. Spec Care Dentist. 2003;23(3):108-10. doi: 10.1111/j.1754-4505.2003.tb01670.x. Spec Care Dentist. 2003. PMID: 14650559

7

Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation.

Vogl DT, Glatstein E, Carver JR, Schuster SJ, Stadtmauer EA, Luger S, Nasta SD, Porter DL, Elstrom R, Tsai DE. Vogl DT, et al. Among authors: porter dl. Leuk Lymphoma. 2005 Sep;46(9):1313-20. doi: 10.1080/10428190500158649. Leuk Lymphoma. 2005. PMID: 16109609

8

Serum protein electrophoresis abnormalities in adult solid organ transplant patients with post-transplant lymphoproliferative disorder.

Tsai DE, Aqui NA, Tomaszewski JE, Olthoff KM, Ahya VN, Kotloff RM, Bloom RD, Brozena SC, Hodinka RL, Stadtmauer EA, Schuster SJ, Nasta SD, Porter DL, Luger SM, Klumpp TR. Tsai DE, et al. Among authors: porter dl. Clin Transplant. 2005 Oct;19(5):644-52. doi: 10.1111/j.1399-0012.2005.00388.x. Clin Transplant. 2005. PMID: 16146557

9

A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation.

Porter DL, Levine BL, Bunin N, Stadtmauer EA, Luger SM, Goldstein S, Loren A, Phillips J, Nasta S, Perl A, Schuster S, Tsai D, Sohal A, Veloso E, Emerson S, June CH. Porter DL, et al. Blood. 2006 Feb 15;107(4):1325-31. doi: 10.1182/blood-2005-08-3373. Epub 2005 Nov 3. Blood. 2006. PMID: 16269610 Free article. Clinical Trial.

10

A predictive model for the detection of tumor lysis syndrome during AML induction therapy.

Mato AR, Riccio BE, Qin L, Heitjan DF, Carroll M, Loren A, Porter DL, Perl A, Stadtmauer E, Tsai D, Gewirtz A, Luger SM. Mato AR, et al. Among authors: porter dl. Leuk Lymphoma. 2006 May;47(5):877-83. doi: 10.1080/10428190500404662. Leuk Lymphoma. 2006. PMID: 16753873

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

239 results

Search Page